Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China

The international CONFIRM study showed that fulvestrant 500 mg improved progression-free survival (PFS) vs fulvestrant 250 mg in postmenopausal women with estrogen receptor (ER)-positive locally advanced/metastatic breast cancer (LA/MBC). In this randomized, double-blind study, postmenopausal Chines...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qingyuan, Shao, Zhimin, Shen, Kunwei, Li, Li, Feng, Jifeng, Tong, Zhongsheng, Gu, Kangsheng, Wang, Xiaojia, Xu, Binghe, Sun, Guofang, Chen, Huifang, Rukazenkov, Yuri, Jiang, Zefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302990/
https://www.ncbi.nlm.nih.gov/pubmed/27359058
http://dx.doi.org/10.18632/oncotarget.10254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302990/
https://www.ncbi.nlm.nih.gov/pubmed/27359058
http://dx.doi.org/10.18632/oncotarget.10254

Ejemplares similares